Novartis Announces Plan To Initiate Clinical Trial Of Canakinumab For Patients With Covid-19 Pneumonia

Novartis Announces Plan To Initiate Clinical Trial Of Canakinumab For Patients With Covid-19 Pneumonia

By, Admin 29 April 2020

Novartis Today Announced Plans To Initiate A Phase Iii Clinical Trial To Study Canakinumab In Patients With Covid-19 Pneumonia. The Can-Covid Trial Will Examine The Efficacy Of Utilizing Canakinumab, An Interleukin (Il)-1Β Blocker, To Treat A Type Of Severe Immune Overreaction Called Cytokine Release Syndrome (Crs) In People With Covid-19 Pneumonia. Crs Could Lead To Life-Threatening Complications In Patients With Covid-19.(1-3)The Study Builds On Early Evidence From Lab Tests Of Covid-19 Patients Who Showed Elevated Il-1Β Levels, Among Other Cytokines.(2,4)Novartis Aims To Rapidly Enroll 450 Patients At Multiple Medical Centers Across France, Germany, Italy, Spain, Uk And The Us And Randomize Them To Receive Either Canakinumab Or Placebo On Top Of Standard Of Care (Soc). The Primary Objective Of The Study Is To Demonstrate The Benefit Of Canakinumab In Combination With Soc In Increasing The Chance Of Survival Without The Need For Invasive Mechanical Ventilation Among Patients With Covid-19 Pneumonia. Top-Line Results Are Anticipated Late Summer 2020.This Trial Initiation Is Part Of The Overall Novartis Approach To Applying Our Best Science To Tackling The Issues Related To Covid-19 And Further Underscores Novartis Commitment To Quickly Deploy R&Amp;D Resources, Medicines, Clinical Expertise And Philanthropic Aid To Combat Covid-19. About NovartisNovartis Is Reimagining Medicine To Improve And Extend People&Rsquo;S Lives. As A Leading Global Medicines Company, We Use Innovative Science And Digital Technologies To Create Transformative Treatments In Areas Of Great Medical Need. In Our Quest To Find New Medicines, We Consistently Rank Among The World&Rsquo;S Top Companies Investing In Research And Development. Novartis Products Reach Nearly 800 Million People Globally And We Are Finding Innovative Ways To Expand Access To Our Latest Treatments. About 109,000 People Of More Than 145 Nationalities Work At Novartis Around The World.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!